Kyoto, Japan, February 21, 2022— Thyas Co. Ltd., a Kyoto-based biotechnology company developing induced pluripotent stem cell (iPSC)-derived immune cell therapies for cancer and infectious diseases, announced today the closing of JPY 2.1B Series B financing. The financing was co-led by Eight Roads Ventures Japan and F-Prime Capital Partners, the world’s leading healthcare investor group, with follow-on participation by D3 LLC, a Japanese investor specialized in the bio-healthcare field.

Click here for more details.